Physician profile
Patrick M Murray
NPI 1639144470
$9,207.21
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,470 · 2020: $926 · 2021: $1,353 · 2022: $1,342 · 2023: $1,604 · 2024: $1,511.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,115.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,134.02 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $1,718.66 | 2019-2024 | Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $1,154.75 | 2019-2022 | |
| Glaxosmithkline, LLC. | $1,092.44 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Kowa Pharmaceuticals America, INC. | $462.54 | 2019-2024 | Livalo, Seglentis, Zoryve |
| Novo Nordisk INC | $368.14 | 2019-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $349.51 | 2019-2024 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $318.17 | 2019-2024 | Jardiance, Tradjenta, Stiolto Respimat |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $301.90 | 2019-2024 | Xifaxan |
| Allergan, INC. | $209.85 | 2019-2020 | |
| Abbvie INC. | $159.21 | 2021-2024 | |
| Pfizer INC. | $156.48 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $129.12 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $127.60 | 2019-2021 | |
| Astellas Pharma US INC | $112.20 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $105.34 | 2019-2023 | Eliquis |
| Amarin Pharma, INC. | $65.18 | 2019-2020 | |
| Exact Sciences Corporation | $60.86 | 2023-2024 | Cologuard Collection Kit |
| Abbott Laboratories | $50.17 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Dexcom, INC. | $27.02 | 2024 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $21.63 | 2019 | |
| Axonics, INC. | $19.83 | 2023 | Axonics |
| Biohaven Pharmaceuticals, INC. | $17.10 | 2021 | |
| Arbor Pharmaceuticals, INC. | $15.35 | 2021 | |
| Eisai INC. | $15.28 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Murray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.